Centessa   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: London United Kingdom (2014)

Organization Overview

First Clinical Trial
2019
NCT04073498
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ApcinteX Ltd | Centessa Pharmaceuticals plc | Centessa Pharmaceuticals (UK) Limited | Z Factor Limited

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: Centessa (0) Acquired (1)

lixivaptan (5 trials)

Drugs in Phase 2 Trials (2)

alpha-1 antitrypsin (Prolastin) (3 trials)

lb101 (1 trial)

Drugs in Phase 1 Trials (2)

CBS001 (1 trial)

zf874 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

alpha 1-Antitrypsin Deficiency (Phase 1)

Hemophilia A (Phase 2)

Hemophilia B (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 5